The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in the coming months. Novo Nordisk expects the Wegovy pill to be available widely in January, a company spokesperson said. GLP-1 drugs — which include semaglutide, the drug in Novo Nordisk’s Ozempic and Wegovy, and tirzepatide, the drug in Lilly’s Mounjaro and Zepbound — have soared in popularity in recent years. The compounds, initially approved for diabetes, can also offer significant weight loss. The drugs all come in an injectable form. (Novo Nordisk does make one pill version of semaglutide, called Rybelsus, for diabetes. It comes in a lower dose than the new version for weight loss.)

Full report : FDA approves Wegovy weight loss pill from Novo Nordisk.